Novartis's Sandoz Signs Deal to Commercialize Polpharma's Proposed Biosimilar Natalizumab
September 03 2019 - 2:02AM
Dow Jones News
By Max Bernhard
Novartis AG's (NOVN.EB) biosimilars division Sandoz has signed a
global agreement with Polpharma SA for the commercialization of a
proposed natalizumab biosimilar, the company said Tuesday.
The medicine is in phase 3 clinical development for the
treatment of relapsing-remitting multiple sclerosis, Novartis
said.
Under the deal, Polpharma will maintain responsibilities for
development, manufacturing and supply of proposed biosimilar
natalizumab. Sandoz will commercialize and distribute the medicine
in all markets upon approval, through an exclusive global license,
the company said.
Other terms of the agreement are confidential, it said.
Write to Max Bernhard at max.bernhard@dowjones.com;
@mxbernhard
(END) Dow Jones Newswires
September 03, 2019 01:47 ET (05:47 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024
